A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: Androstene hormones as regulators of regulatory T cells

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 630-640

  Auci, Dominick L ^a,d   Kaler, L ^b   Subramanian, Sandhya ^b   Huang, Yugin ^a   Frincke, J ^a   Reading, C ^a   Offner, H ^b,c  

^a HollisEden Pharmaceuticals   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d 4435 Eastgate Mall ^*  (United States)

Author keywords

Androstene; Arthritis; Cytokines; DHEA metabolites; Regulatory T cells

Indexed keywords

ANDROSTANE DERIVATIVE; CYTOKINE; HE3286; HORMONE; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; MITOGENIC AGENT; PRASTERONE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; AUTOIMMUNE DISEASE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL COUNT; CELL FUNCTION; COLLAGEN INDUCED ARTHRITIS; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; DBA MOUSE; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG POTENCY; EROSION; HISTOLOGY; INFECTION; KNOWLEDGE; MALE; MASS; MIXED LYMPHOCYTE REACTION; MOUSE; NEOPLASM; NONHUMAN; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYNOVIUM;

ANIMALIA; MUS; RODENTIA;

EID: 35748933207     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.066     Document Type: Conference Paper

References (40)

1. TANEJA, V. et al. 2002. CD4 and CD8T cells in susceptibility/protection to collagen-induced arthritis in HLA-DQ8-transgenic mice: implications for rheumatoid arthritis. J. Immunol. 168: 5867-5875.
2. MYERS, L.K. et al. 1998. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J. Immunol. 161: 3589-3595.
3. JOOSTEN, L.A. et al. 1999. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 163: 5049-5055.
4. QUATTROCCHI, E. et al. 1999. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. J. Immunol. 163: 1000-1009.
5. MARINOVA-MUTAFCHIEVA, L. et al. 2002. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum. 46: 507-513.
6. ZWAR, T.D., I.R. VAN DRIEL & P.A. GLEESON. 2007. Guarding the immune system: Suppression of autoimmunity by CD4CD25 immunoregulatory T cells. Immunol. Cell Biol. 84: 487-501. [e-pub 2006 Sep 5]
7. POLANCZYK, M.J. et al. 2005. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J. Neuroimmunol. 170: 85-92.
8. POLANCZYK, M.J. et al. 2006. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J. Neurosci. Res. 84: 370-378.
9. WHITACRE, C.C., S.C. REINGOLD & P.A. O'LOONEY. 1999. A gender gap in autoimmunity. Science 283: 1277-1278.
10. ROUBINIAN, J.R., R. PAPOIAN & N. TALAL. 1977. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J. Clin. Invest. 59: 1066-1070.
11. MAKINO, S. et al. 1981. Effect of castration on the appearance of diabetes in NOD mouse. Jikken Dobutsu 30: 137-140.
12. AHMED, S.A. & W.J. PENHALE. 1982. The influence of testosterone on the development of autoimmune thyroiditis in thymectomized and irradiated rats. Clin. Exp. Immunol. 48: 367-374.
13. ALLEN, J.B. et al. 1983. Sex hormonal effects on the severity of streptococcal cell wall-induced polyarthritis in the rat. Arthritis Rheum. 26: 560-563.
14. VOSKUHL, R.R. et al. 1996. Gender differences in autoimmune demyelination in the mouse: implications for multiple sclerosis. Ann. Neurol. 39: 724-733.
15. BEBO, B.F., JR., A.A. VANDENBARK & H. OFFNER. 1996. Male SJL mice do not relapse after induction of EAE with PLP 139-151. J. Neurosci. Res. 45: 680-689.
16. BLAZKOVEC, A.A. & M.W. ORSINI. 1976. Ontogenetic aspects of sexual dimorphism and the primary immune response to sheep erythrocytes in hamsters from prepuberty through senescence. Int. Arch. Allergy Appl. Immunol. 50: 55-67.
17. OKA, M. & U. VAINIO. 1966. Effect of pregnancy on the prognosis and serology of rheumatoid arthritis. Acta Rheumatol. Scand. 12: 47-52.
18. CONFAVREUX, C. et al. 1998. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339: 285-291.
19. HANSON, G.C. & S. GHOSH. 1965. Systemic lupus erythematosus and pregnancy. Br. Med. J. 2: 1227-1228.
20. OSTENSEN, M. & G. HUSBY. 1983. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 26: 1155-1159.
21. SMALL, M. et al. 1989. Adrenal androgens in insulin-dependent diabetes mellitus. Diabetes Res. 11: 93-95.
22. HENDERSON, E. et al. 1981. Dehydroepiandrosterone and 16 alpha-bromoepiandrosterone: inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes. Carcinogenesis 2: 683-686.
23. KHAW, K.T. 1996. Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease. J. Endocrinol. 150(Suppl): S149-S153.
24. VANVOLLENHOVEN, R.F. et al. 1999. VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics. J. Rheumatol. 26: 1727-1733.
25. DU, C., M.W. KHALIL & S. SRIRAM. 2001. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J. Immunol. 167: 7094-7101.
26. YEN, T.T. et al. 1977. Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids 12: 409-413.
27. BEN-DAVID, M. et al. 1967. Anti- hypercholesterolemic effect of dehydroepiandrosterone in rats. Proc. Soc. Exp. Biol. Med. 125: 1136-1140.
28. VAN VOLLENHOVEN, R.F. et al. 1999. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus [see comments]. Lupus 8: 181-187.
29. OFFNER, H. et al. 2004. A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse. Clin. Immunol. 110: 181-190.
30. JOHNSTON, G. & Y. SO. 2003. Analysis of data from recurrent events [paper 273]. Proceedings of the Twenty-Eight Annual SAS Users Group International Conference, March 30 - April 2, 2003:1-8.
31. CONOVER, W.J. & R.L. IMAN. 1982. Analysis of covariance using the rank transformation. Biometrics 38: 715-724.
32. MARWAH, A., P. MARWAH & H. LARDY. 2002. Ergosteroids. VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. J. Chromatogr. B. Biomed. Sci. Appl. 767: 285-299.
33. EBELING, P. & V.A. KOIVISTO. 1994. Physiological importance of dehydroepiandrosterone. Lancet 343: 1479-1481.
34. GALON, J. et al. 2002. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16: 61-71.
35. AUCI, D.L. et al. 2003. The immunobiology and therapeutic potential of androstene hormones and their synthetic derivatives: novel anti-inflammatory and immune regulating steroid hormones. Mod. Asp. Immunobiol. 3: 64-70.
36. PIETERS, R. 2001. The popliteal lymph node assay: a tool for predicting drug allergies. Toxicology 158: 65-69.
37. KEITH, J.C., JR. et al. 2005. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. Arthritis Res. Ther. 7: R427-R438.
38. TAN, P.H. et al. 2005. Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J. Immunol. 174: 7633-7644.
39. HERNANDEZ-PANDO, R. et al. 2005. 16a-bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in model of progressive pulmonary tuberculosis. J. Infect. Dis. 191: 299-306.
40. STICKNEY, D. et al. 2007. Safety and activity of the immune modulator HE 2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients. Antimicrob. Agents Chemother. 51: 2639-2641.